Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude sur le Patritumab Deruxtecan avec d'autres agents anticancéreux chez des participantes atteintes d'un cancer du sein HER2 positif qui s'est propagé et ne peut pas être retiré chirurgicalement (MK-1022-009)

12 novembre 2026 mis à jour par: Merck Sharp & Dohme LLC

HERTHENA-Breast-01 : Une étude de phase 1b/2, multicentrique, ouverte, de recherche de dose pour évaluer l'innocuité et l'activité antitumorale du Patritumab Deruxtecan chez les participantes atteintes d'un cancer du sein localement avancé non résécable HER2 positif ou d'un cancer du sein métastatique

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:

  • About the safety and how well people tolerate of patritumab deruxtecan
  • How many people have the cancer respond (get smaller or go away) to treatment

Aperçu de l'étude

Description détaillée

The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.

Type d'étude

Interventionnel

Inscription (Estimé)

181

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Ontario
      • Kingston, Ontario, Canada, K7L 2V7
        • Recrutement
        • Kingston General Hospital ( Site 0061)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 6135336541
      • Toronto, Ontario, Canada, M5G 2M9
        • Recrutement
        • Princess Margaret Cancer Centre ( Site 0001)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 416-946-4501
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Recrutement
        • Jewish General Hospital ( Site 0003)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 514-340-8222
      • Montreal, Quebec, Canada, H2X 3E4
        • Recrutement
        • Centre Hospitalier de l'Université de Montréal ( Site 0004)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: (514)890-8000 x20737
      • Seoul, Corée du Sud, 03080
        • Recrutement
        • Seoul National University Hospital ( Site 0030)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 82-2-2072-0850
      • Seoul, Corée du Sud, 05505
        • Recrutement
        • Asan Medical Center ( Site 0031)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82-2-1688-7575
      • Haifa, Israël, 3109601
        • Recrutement
        • Rambam Health Care Campus ( Site 0011)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 04-7776234
      • Petah Tikva, Israël, 4941492
        • Recrutement
        • Rabin Medical Center ( Site 0012)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +972-505533121
      • Ramat Gan, Israël, 5265601
        • Recrutement
        • Sheba Medical Center ( Site 0010)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 03-5304498
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 467-8602
        • Recrutement
        • Nagoya City University Hospital ( Site 0020)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +81-52-851-5511
    • Camden
      • London, Camden, Royaume-Uni, NW1 2PG
        • Recrutement
        • University College London Hospital ( Site 0041)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +442034472930
    • Glasgow City
      • Glasgow, Glasgow City, Royaume-Uni, G12 0YN
        • Recrutement
        • The Beatson West of Scotland Cancer Centre ( Site 0043)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +441413017000
    • London, City of
      • London, London, City of, Royaume-Uni, EC1A 7BE
        • Recrutement
        • St Bartholomew s Hospital ( Site 0040)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +442073777000
    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • Recrutement
        • University of Colorado Anschutz Medical Campus ( Site 0057)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 720-848-1030
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Recrutement
        • Dana-Farber Cancer Institute ( Site 0050)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 877-338-7425
    • New Jersey
      • New Brunswick, New Jersey, États-Unis, 08901
        • Recrutement
        • Rutgers Cancer Institute of New Jersey ( Site 0052)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 732-235-2465
    • South Carolina
      • Greenville, South Carolina, États-Unis, 29605
        • Recrutement
        • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 864-455-3600
    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Recrutement
        • Inova Schar Cancer Institute ( Site 0051)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 571-472-4724

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
  • Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention

Part 1 Arm 1:

  • Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
  • Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment

Part 1 Arm 2:

-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting

Part 1 Arm 3:

-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.

Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Uncontrolled or significant cardiovascular disease
  • Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
  • Has clinically severe respiratory compromise
  • Has any history of or evidence of any current leptomeningeal disease
  • Has clinically significant corneal disease
  • Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
  • HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Part 1: Evidence of spinal cord compression or brain metastases
  • Part 2: Evidence of spinal cord compression or brain/CNS metastases.
  • Has an active infection requiring systemic therapy
  • Concurrent active HBV and HCV infection
  • Has had major surgical procedure (excluding placement of vascular access) less than 28 days

Part1: Arm 3 ONLY

- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part 1: Patritumab deruxtecan plus trastuzumab

Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Autres noms:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Autres noms:
  • Herceptine®

Trastuzumab biosimilar administered via IV infusion

Autres noms:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®
Expérimental: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Autres noms:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Autres noms:
  • Herceptine®

Trastuzumab biosimilar administered via IV infusion

Autres noms:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Expérimental: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib

Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Autres noms:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Autres noms:
  • Herceptine®

Trastuzumab biosimilar administered via IV infusion

Autres noms:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Tucatinib administered as oral tablets

Expérimental: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Autres noms:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Autres noms:
  • Herceptine®

Trastuzumab biosimilar administered via IV infusion

Autres noms:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Délai: Up to 21 days

DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Délai: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Délai: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Up to approximately 12 months
Part 2: Objective Response Rate (ORR)
Délai: Up to approximately 36 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented.

Up to approximately 36 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Délai: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 2: Duration of Response (DOR)
Délai: Up to approximately 36 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Progression Free Survival (PFS)
Délai: Up to approximately 36 months

PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Number of Participants with One or More AEs
Délai: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Délai: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Directeur d'études: Medical Director, Merck Sharp & Dohme LLC

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 février 2025

Achèvement primaire (Estimé)

2 août 2032

Achèvement de l'étude (Estimé)

2 août 2032

Dates d'inscription aux études

Première soumission

11 novembre 2024

Première soumission répondant aux critères de contrôle qualité

11 novembre 2024

Première publication (Réel)

13 novembre 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 1022-009
  • MK-1022-009 (Autre identifiant: MSD)
  • jRCT2041250022 (Identificateur de registre: Japan Registry of Clinical Trials (jRCT))
  • 2026-528266-19 (Identificateur de registre: EU CT)
  • U1111-1346-4321 (Identificateur de registre: UTN)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner